Study of 9MW3011 in adults with beta-thalassemia without regular transfusions
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new drug, 9MW3011, in people with a type of beta-thalassemia that does not require regular blood transfusions. The goal is to see if the drug can safely help manage iron overload and improve hemoglobin levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been diagnosed with beta-thalassemia (or hemoglobin E/beta-thalassemia) and do not need regular blood transfusions
- Your hemoglobin level is between 70 and 100 g/L (a measure of red blood cells)
- You have too much iron in your body (iron overload) at the screening visit
- You are generally able to do daily activities (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CS-101 for people with beta-thalassemia who need regular blood transfusions. It aims to see if CS-101 can help reduce transfusion needs.
This trial tests a new gene therapy for beta thalassemia. A modified virus is used to deliver a working gene to your blood stem cells, which may help your body produce normal hemoglobin and reduce the need for blood transfusions.
This early study tests the safety and potential benefit of the LentiRed gene-based drug in people with transfusion-dependent beta-thalassemia (TDT) who are planning an autologous stem cell transplant. It may help reduce the severity of anemia, but the main goal at this stage is to check safety and side effects.
This study tests an experimental gene-editing treatment called CS-101 for people with severe beta-thalassemia who need regular blood transfusions. The goal is to see if it can reduce or eliminate the need for transfusions by helping the body make more healthy red blood cells.
This Phase 1 study tests a new medicine (GMCN-508A) to see how safe it is and whether it can help people with transfusion-dependent alpha thalassemia. Participants are also expected to follow a treatment plan that includes stem cell transplantation preparation.
This study tests an experimental medicine called YOLT-204 for people with beta-thalassemia who need regular blood transfusions. The goal is to see if this treatment is safe and if it might reduce the need for transfusions.
Hear when a new Beta-Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.